FDA grants accelerated approval to Rocket Pharmaceuticals’ KRESLADI™ for ultra-rare pediatric immune disorder
Rocket Pharmaceuticals (NASDAQ:RCKT), a leading biotechnology firm specializing in genetic therapies for rare disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for KRESLADI™ (marnetegragene autotemcel).


_1370415_640x360_2493999171948-640x360.webp&w=1200&q=75)

_1370379_640x360_2493999683758-640x360.webp&w=1200&q=75)
_1370367_640x360_2493999683647-640x360.webp&w=1200&q=75)



